Neurocrine Biosciences and Takeda Announce Collaboration to Develop and Market Potential Therapies for Psychiatric Disorders
Wednesday, June 17, 2020
Neurocrine Biosciences, Inc and Takeda Pharmaceutical Company Limited announced a strategic collaboration for the development and marketing of compounds in the initial and intermediate phases of Takeda's psychiatric pipeline. Takeda has granted an exclusive license to Neurocrine Biosciences for seven pipeline programs, including three active in clinical phase for schizophrenia, treatment-resistant depression and anhedonia.
"We are delighted to be working alongside Takeda to bring breakthrough therapies to people with severe and complex psychiatric conditions who need better treatment options," said Kevin Gorman, Ph.D., CEO of Neurocrine Biosciences. “With our extensive expertise in psychiatry and neurology, we are ready to develop new treatments for schizophrenia, treatment-resistant depression and anhedonia as part of our diverse clinical development pipeline. This strategic partnership is expanding our portfolio and strengthening our position as a biopharmaceutical leader specializing in neuroscience. ”
“With a wealth of experience in the development and marketing of therapies for severe neurological and psychiatric disorders, Neurocrine Biosciences is the ideal partner to continue strengthening our psychiatric portfolio in the initial and intermediate phases and to offer these new therapies to patients, ”said Sarah Sheikh, DM, M.Sc., MRCP, head of the neuroscience therapy unit at Takeda. “Takeda is resolutely committed to neuroscience as a key therapeutic sector. The strategic partnership with Neurocrine Biosciences allows us to continue to consolidate our leadership in psychiatry and to bring new drugs to these patients, while advancing our clinical assets for rare diseases, such as narcolepsy,
